Journal of Clinical Oncology, Vol 13, 424-429, Copyright © 1995 by American Society of Clinical Oncology
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer
IE Smith, G Walsh, A Jones, J Prendiville, S Johnston, B Gusterson, F Ramage, H Robertshaw, N Sacks and S Ebbs
Breast Unit, Royal Marsden Hospital, London, England.
PURPOSE: To investigate the efficacy of continuous infusion fluorouracil
(5FU) with every-3-week epirubicin and cisplatin (ECF) as primary
chemotherapy instead of immediate mastectomy for patients with large,
potentially operable, breast cancer. PATIENTS AND METHODS: Fifty patients
with large operable breast cancer, median tumor diameter 6 cm (range, 3 to
12), were treated with 5FU 200 mg/m2/d via a Hickman line using an
ambulatory pump for 6 months with epirubicin 50 mg/m2 intravenously (IV)
and cisplatin 60 mg/m2 IV every 3 weeks for eight courses. Subsequent
surgery and/or radiotherapy was determined by clinical response. RESULTS:
Forty-nine patients achieved an overall response (98%; 95% confidence
interval [CI], 94% to 100%), including 33 complete clinical remissions
(CRs) (66%; 95% CI, 53% to 79%). Only three patients (6%) still required
mastectomy. Tumor cellularity was markedly reduced on repeat needle biopsy
following 3 weeks of treatment in 81% of patients versus only 36% in
similar patients after conventional chemotherapy (P < .002). Severe
(World Health Organization [WHO] grade 3 to 4) toxicity was rare, with
nausea/vomiting being the most common, occurring in 20% of patients.
CONCLUSION: Primary infusional ECF appears to be more active on clinical
and histopathologic grounds than conventional chemotherapy for large
operable breast cancer and is well tolerated. This approach now merits
randomized comparison to determine if high CR rates may translate into
improved survival.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Sirohi, M. Arnedos, S. Popat, S. Ashley, A. Nerurkar, G. Walsh, S. Johnston, and I. E. Smith
Platinum-based chemotherapy in triple-negative breast cancer
Ann. Onc.,
November 1, 2008;
19(11):
1847 - 1852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al.
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival
Clin. Cancer Res.,
March 1, 2006;
12(5):
1501 - 1506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. W. Moon, S. Y. Rha, H. C. Jeung, W. I. Yang, C. O. Suh, and H. C. Chung
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
Ann. Onc.,
November 1, 2005;
16(11):
1778 - 1785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chua, I. E. Smith, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E. R. O'Brien, S. R. Ebbs, A. Hong, et al.
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
Ann. Onc.,
September 1, 2005;
16(9):
1435 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al.
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
J. Clin. Oncol.,
May 1, 2005;
23(13):
2988 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease
Clin. Cancer Res.,
October 1, 2004;
10(19):
6418 - 6431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. E. Smith, R. P. A'Hern, G. A. Coombes, A. Howell, S. R. Ebbs, T. F. Hickish, M. E. R. O'Brien, J. L. Mansi, C. B. Wilson, A. C. Robinson, et al.
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
Ann. Onc.,
May 1, 2004;
15(5):
751 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Ring, A. Webb, S. Ashley, W.H. Allum, S. Ebbs, G. Gui, N.P. Sacks, G. Walsh, and I.E. Smith
Is Surgery Necessary After Complete Clinical Remission Following Neoadjuvant Chemotherapy for Early Breast Cancer?
J. Clin. Oncol.,
December 15, 2003;
21(24):
4540 - 4545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Joensuu
Primary chemotherapy of breast cancer followed by perioperative chemotherapy: feasible, but are there clinical benefits?
Ann. Onc.,
October 1, 2003;
14(10):
1460 - 1462.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Colleoni, G. Curigliano, I. Minchella, G. Peruzzotti, F. Nole, G. Mazzarol, G. Renne, L. Orlando, A. Rocca, P. Veronesi, et al.
Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase
Ann. Onc.,
October 1, 2003;
14(10):
1477 - 1483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Danforth Jr, K. Cowan, R. Altemus, M. Merino, C. Chow, A. Berman, U. Chaudhry, C. Shriver, S. M. Steinberg, and J. Zujewski
Preoperative FLAC/Granulocyte-Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer: A Prospective Randomized Trial
Ann. Surg. Oncol.,
July 1, 2003;
10(6):
635 - 644.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kaufmann, G. von Minckwitz, R. Smith, V. Valero, L. Gianni, W. Eiermann, A. Howell, S. D. Costa, P. Beuzeboc, M. Untch, et al.
International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations
J. Clin. Oncol.,
July 1, 2003;
21(13):
2600 - 2608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Parton, S. Krajewski, I. Smith, M. Krajewska, C. Archer, M. Naito, R. Ahern, J. Reed, and M. Dowsett
Coordinate Expression of Apoptosis-associated Proteins in Human Breast Cancer before and during Chemotherapy
Clin. Cancer Res.,
July 1, 2002;
8(7):
2100 - 2108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. De Boer, T. G. Eisen, P. A. Ellis, S. R. D. Johnston, G. Walsh, S. Ashley, and I. E. Smith
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer
Ann. Onc.,
June 1, 2002;
13(6):
889 - 894.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Munzone, F. Nole, L. Orlando, M. Mandala, R. Biffi, C. Ciano, G. Villa, M. Civelli, and A. Goldhirsch
Unexpected Right Phrenic Nerve Injury During 5-Fluorouracil Continuous Infusion Plus Cisplatin and Vinorelbine in Breast Cancer Patients
J Natl Cancer Inst,
May 3, 2000;
92(9):
755 - 755.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Wolff and N. E. Davidson
Primary Systemic Therapy in Operable Breast Cancer
J. Clin. Oncol.,
April 7, 2000;
18(7):
1558 - 1569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Mackay, D. Cameron, M. Rahilly, M. J. Mackean, J. Paul, S. B. Kaye, and R. Brown
Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival
J. Clin. Oncol.,
January 5, 2000;
18(1):
87 - 87.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. von Minckwitz, S. D. Costa, W. Eiermann, J.-U. Blohmer, A. H. Tulusan, C. Jackisch, and M. Kaufmann
Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and Docetaxel
J. Clin. Oncol.,
July 1, 1999;
17(7):
1999 - 1999.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. K. Working, M. S. Newman, T. Sullivan, and J. Yarrington
Reduction of the Cardiotoxicity of Doxorubicin in Rabbits and Dogs by Encapsulation in Long-Circulating, Pegylated Liposomes
J. Pharmacol. Exp. Ther.,
May 1, 1999;
289(2):
1128 - 1133.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M Amantea, M S Newman, T M Sullivan, A Forrest, and P K Working
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
Human and Experimental Toxicology,
January 1, 1999;
18(1):
17 - 26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Epstein
Treating breast cancer before surgery
BMJ,
November 30, 1996;
313(7069):
1345 - 1346.
[Full Text]
|
|
|
|
